BeiGene
National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.
August 6, 2024Research and Development BeiGene, National Institute of Healthcare and Excellence, Oncology, lymphoma, margina zone lymphoma, orphan disease
BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE)Â for treatment …
BeiGene’s Brukinsa gains FDA accelerated approval for follicular lymphoma treatment
March 8, 2024Medical Communications BeiGene, Brukinsa, FDA, Oncology, follicular lymphoma
BeiGene has announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib) for the …
BeiGene’s tislelizumab gets China approval for non-small cell lung cancer
January 14, 2021BeiGene, Cancer, tislelizumab
BeiGene Ltd has announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) …
Novartis and BeiGene join forces to develop cancer drug tislelizumab
January 12, 2021Manufacturing and Production BeiGene, Cancer, Novartis
Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene Ltd in major markets outside of China, accelerating …
Amgen drops $2.7bn to acquire stake in Chinese biotech in bid to expand in the region
November 1, 2019Medical Communications, Research and Development, Sales and Marketing Amgen, BeiGene, Cancer, China, deal, oncology, pharma
Amgen has signed an agreement with Chinese biotech BeiGene to acquire a 20.5% stake in the latter, in a bid …
Celgene plays catch up with $1.4 billion immunotherapy deal
July 7, 2017Medical Communications, Sales and Marketing BeiGene, Celgene, immunotherapy, pd-1
Those commentating on Celgene’s latest deal seem to be equally divided between two camps: it is too much money, too …
BeiGene to develop $330 million biologics plant
March 7, 2017Manufacturing and Production, Research and Development BeiGene, China, Guangzhou
BeiGene, a Chinese biotech company, and Guangzhou GET Technology Development, an affiliate of Guangzhou Development District, will partner in the …
Latest content
Five Facts about cardiovascular disease
